CompletedPhase 2

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis

United States189 participantsStarted 2021-08-18

Plain-language summary

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Chronic hepatitis B (HBV) or hepatitis C virus (HCV) infection (However, If the subject has been treated for the HCV infection and has been cured at least 5 years from screening, such subjects can be enrolled in the study)
✕. Primary biliary cholangitis (PBC)
✕. Primary sclerosing cholangitis (PSC)
✕. Definite autoimmune liver disease or overlap syndrome
✕. Alcoholic liver disease
✕. Hemochromatosis
✕. Wilsons disease
✕. Alpha-1 antitrypsin deficiency

Resolution of steatohepatitis with no worsening of fibrosis

Timeframe: 52 Weeks/EOT

NCT IDNCT05011305

SponsorZydus Therapeutics Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-09-12